WIRB-Copernicus Group Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • WIRB-Copernicus Group's estimated annual revenue is currently $267.3M per year.(i)
  • WIRB-Copernicus Group's estimated revenue per employee is $201,000

Employee Data

  • WIRB-Copernicus Group has 1330 Employees.(i)
  • WIRB-Copernicus Group grew their employee count by 6% last year.

WIRB-Copernicus Group's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CMOReveal Email/Phone
3
Chief Commercial Officer, Ethical Review DivisionReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
VP, Chief Information Security OfficerReveal Email/Phone
6
Chief Change OfficerReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Chief Information OfficerReveal Email/Phone
9
Chief Technology OfficerReveal Email/Phone
10
Chief Commercial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is WIRB-Copernicus Group?

WCG is the world's largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG's solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life. For more information, please visit www.wcgclinical.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

1330

Number of Employees

$267.3M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

WIRB-Copernicus Group News

2022-04-06 - Electronic Trial Master File Systems Market Size to grow by USD ...

WIRB Copernicus Group. Find additional highlights on the growth strategies adopted by vendors and their product offerings. Read Free Sample...

2022-02-22 - WCG Introduces a Transformational Total Safety Solution for ...

WCG Total Safety™ provides turnkey management of drug safety, pharmacovigilance, and safety reporting technology to meet demanding regulatory...

2021-07-26 - WCG Expands Clinical Trial Technology and Services with Acquisition of VeraSci

PRINCETON, N.J., July 26, 2021 /PRNewswire/ -- WCG today announced the acquisition of VeraSci, a global provider of specialty scientific expertise and eClinical software to support the design and execution of clinical trials focused on central nervous system (CNS) disorders. The addition of Ve ...

2020-12-03 - WCG Acquires Trifecta, a Global Leader in Clinical Trial Site Communications

PRINCETON, N.J., Dec. 3, 2020 /PRNewswire/ -- WCG today announced its acquisition of Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace®, virtual training programs and safety documentation ...

2019-08-27 - WCG Introduces Velos eResearch eXpress™

PRINCETON, N.J., Aug. 27, 2019 /PRNewswire/ -- The WIRB-Copernicus Group®'s (WCG™) Clinical Services Division introduces Velos ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$420.7M13668%N/A
#2
$302.3M1489N/AN/A
#3
$275.4M15547%N/A
#4
$336.1M1715N/AN/A
#5
$350.4M172624%N/A

WIRB-Copernicus Group Funding

DateAmountRoundLead InvestorsReference
2017-05-10$3043295Article
2018-07-26$2604337Article